


## Tacrolimus monohydrate

<b>Cat. No.:</b>	HY-13756A
<b>CAS No.:</b>	109581-93-3
<b>Molecular Formula:</b>	C <sub>44</sub> H <sub>71</sub> NO <sub>13</sub>
<b>Molecular Weight:</b>	822
<b>Target:</b>	Phosphatase; FKBP; Autophagy; Bacterial; Antibiotic
<b>Pathway:</b>	Metabolic Enzyme/Protease; Apoptosis; Autophagy; Immunology/Inflammation; Anti-infection
<b>Storage:</b>	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (121.65 mM; Need ultrasonic)				
	H <sub>2</sub> O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	1.2165 mL	6.0827 mL	12.1655 mL
	5 mM	0.2433 mL	1.2165 mL	2.4331 mL	
	10 mM	0.1217 mL	0.6083 mL	1.2165 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties <sup>[1]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	Macrolide	Macrolide
<b>In Vitro</b>	Tacrolimus monohydrate (FK506 monohydrate; Fujimycin monohydrate; FR900506 monohydrate) inhibits calcium-dependent events, such as IL-2 gene transcription, NO synthase activation, cell degranulation, and apoptosis. Tacrolimus also potentiates the actions of glucocorticoids and progesterone by binding to FKBP's contained within the hormone receptor complex, preventing degradation. The agent may enhance expression of the TGFβ-1 gene in a fashion analogous to	

that demonstrated for CsA. T cell proliferation in response to ligation of the T cell receptor is inhibited by Tacrolimus<sup>[1]</sup>. Treatment with a low concentration of Tacrolimus (FK506, 10 µg/L) does not significantly affect the proliferation of MH3924A cells (P=0.135). Upon treatment with higher concentrations of Tacrolimus (100-1,000 µg/L), the proliferation of MH3924A cells is significantly enhanced (P<0.01). Treatment with AMD3100 at any concentration (10, 50 or 100 µg/L), has no obvious effect on MH3924A cell proliferation (P>0.05). However, when different concentrations of AMD3100 are combined with 100 µg/L Tacrolimus, the in vitro proliferation of MH3924A cells is increased (P<0.01)<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

The therapeutic effect of Tacrolimus is investigated on progression and perpetuation of colitis by administering Tacrolimus to Dextran sulfate sodium (DSS)-treated mice from Days 10 to 16 or to 23. At Days 17 and 24, colon length is significantly shortened, and colon weight is significantly higher in DSS-treated control animals than in normal animals. In addition, colon weight per unit length in the control group is more than twice that in the normal group. While both 7 and 14 d treatment with Tacrolimus significantly suppresses increases in colon weight per unit length in DSS-treated animals compared with the control group, this treatment does not actually restore the colon shortening. In addition, this inhibitory effect of Tacrolimus on increases in colon weight per unit length is more pronounced with 14-d than 7-d treatment, as shown by the inhibitory percentages (59% vs. 28%)<sup>[4]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Cell Assay <sup>[3]</sup>

Tumor cell proliferation is determined by the MTT assay. Briefly, after MH3924A cells have reached the logarithmic growth phase, a 0.2-mL cell suspension at  $1 \times 10^4$  cells/mL is added into each well of a 96-well plate and cultured in DMEM with 10% FBS, 10 µg/L vascular endothelial growth factor and 0.1 g/L heparin for 24 h. When adherent growth is established, different concentrations of Tacrolimus (10, 100 and 1,000 µg/L), AMD3100 (10, 50 and 100 µg/L) and Tacrolimus (0 and 100 µg/L) +AMD3100 (0, 10, 50 and 100 µg/L) are added into the plates. Untreated cells cultured in medium alone are used as controls. After culturing for 48 h, 10 µL MTT (5 g/L) are added, and each well is incubated for 6 h; next, 150 µL/well DMSO are added, followed by measurements of the absorbance at 570 nm on a spectrophotometer reader. Each well is measured three times, and each sample is assayed in triplicate<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Animal Administration <sup>[4]</sup>

Mice<sup>[4]</sup>

Six-week-old male C57BL/6J mice are maintained in a temperature- and humidity-controlled room with a 12-h light-dark cycle. For the multiple dosing study, colitic mice (n=10) are orally administered Tacrolimus at 30 mg/kg for 7 d (Days 10 to 16) or 14 d (Days 10 to 23). Control (n=10) and normal groups (n=5) are administered placebo using the same regimen. Tacrolimus or placebo is administered at 10 mL/kg. Mice are euthanized by CO<sub>2</sub> inhalation on the day following the final dosing. For the single dosing study, colitic mice are orally administered Tacrolimus at 30 mg/kg or placebo (n=8) once on Day 7, 10, 17, or 24. Normal mice (n=4) are administered placebo using the same regimen. Mice are euthanized by CO<sub>2</sub> inhalation eight hours after dosing<sup>[4]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Signal Transduct Target Ther. 2023 Nov 1;8(1):417.
- Adv Funct Mater. 2023 Sep 15.
- J Extracell Vesicles. 2019 Dec 27;9(1):1709262.
- Biomaterials. 2021, 120757.
- Theranostics. 2022 Jan 16;12(4):1621-1638.

## REFERENCES

---

- [1]. Thomson AW, et al. Mode of action of Tacrolimus (FK506): molecular and cellular mechanisms. *Ther Drug Monit.* 1995 Dec;17(6):584-91.
- [2]. Vogel KR, et al. mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. *J Inher Metab Dis.* 2016 Nov;39(6):877-886.
- [3]. Zhu H, et al. Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF 1 $\alpha$  expression in vivo. *Mol Med Rep.* 2014 Aug;10(2):585-92.
- [4]. Okada Y, et al. Tacrolimus ameliorates dextran sulfate sodium-induced colitis in mice: implication of interferon- $\gamma$  and interleukin-1 $\beta$  suppression. *Biol Pharm Bull.* 2011;34(12):1823-7.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA